Press Releases

 
Press Releases
Date Title and Summary View
May 13, 2015 SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research programs with advanced...
May 7, 2015 SALT LAKE CITY, May 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present three studies that demonstrate the value of the Prolaris test for physicians and their patients at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La. Key presentations will sh...
May 5, 2015 Total Revenue of $180.0 MillionAdjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk™ Hereditary Cancer Panel Ended Third Quarter at 58 Percent ConversionMyriad Acquires MVZ Clinic to Facilitate Reimbursement in GermanyCompany Provides Fiscal Fourth-Quarter 2015 Financial Guidance SALT LAKE CITY, May 5, 2015 (GLOBE NEWSWIRE) -- My...
Apr 22, 2015 SALT LAKE CITY, April 22, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal third quarter 2015 and provide a business update following the close of market on Tuesday, May 5, 2015. The Company also will host a conference call at 4:30 p.m. ET on May 5, 2015 to discuss ...
Apr 1, 2015 SALT LAKE CITY, April 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad's BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond ...
Mar 20, 2015 SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. "EMPATHY-P showed that ...
Mar 17, 2015 SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced an expansion of the Company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD™ companion diagnostic test to prospectively identify patients with metastatic breast, ova...
Mar 5, 2015 SALT LAKE CITY, March 5, 2015 (GLOBE NEWSWIRE) -- Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc., (Nasdaq:MYGN) today announced the launch of immunoassay services based on the ultrasensitive Simoa™ (single molecule array) platform developed by Quanterix. The Simoa platform enables the accurate measurement of protein biomarkers...
Mar 4, 2015 SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent dia...
Mar 2, 2015 SALT LAKE CITY, March 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetic Laboratories, is scheduled to present at the Barclays Global Healthcare Conference at 11:15 a.m. Eastern on March 11, 2015, at Loews Miami Beach Hotel in Miami Beach, Florida. The presentation will ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase